A new therapy for genetic hearing loss has just been approved by the Food and Drug Administration (FDA). The treatment, Otarmeni (lunsotogene parvec-cwha), is the first-ever dual adeno-associated ...

On April 23, the Food and Drug Administration approved the first-ever gene therapy for a rare, congenital form of deafness. The treatment’s maker, biotechnology company Regeneron, says it plans to ...

In a worldwide first, a one-and-done gene therapy has been approved to treat a form of hereditary deafness. Many of the children treated can hear normally and speak.

Children born deaf because of a rare condition can now take a drug to restore their hearing after a gene therapy was approved in the U.S., ushering in a new era for the treatment of an inherited form ...

The treatment, developed by Regeneron Pharmaceuticals, is for a very rare form of deafness. But it represents a medical milestone.